|
**Overview**: Kappa Free Light Chain Index Panel**Introduction**: The Kappa Free Light Chain Index Panel is a diagnostic tool designed to assess kappa light chain index using serum samples. In India, abnormal kappa/lambda free light chain (FLC) ratio is a sensitive marker for plasma cell dyscrasias including multiple myeloma (MM), light-chain-only MM (~20 percent of cases), AL amyloidosis, and progression risk in MGUS. High morbidity from under-testing in rural/low-SES patients with unexplained anemia, renal impairment, bone pain, or hypercalcemia, limited labs, delayed bortezomib/lenalidomide-based therapy leading to end-organ damage or poor survival. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs immunoassay for kappa free light chain and kappa/lambda ratio over 1-2 days with high accuracy, valuable for early detection, risk stratification, and minimal residual disease monitoring. This diagnostic falls under protein screening and targets patients with suspected monoclonal gammopathy, renal dysfunction, or bone lytic lesions, addressing accurate detection to guide bone marrow biopsy, staging, and treatment initiation. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise FLC ratio assessment and improving myeloma outcomes. Its serum-based approach ensures reliable quantification.**Other Names**: Kappa FLC Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Serum FLC ratio standard since 2000s; in India, routine in myeloma protocols.**Purpose**: The test assesses 2 parameters including kappa free light chain to guide kappa light chain index evaluation, detect abnormal ratio, inform progression risk and monitoring.**Test Parameters**: 1. Kappa Free Light Chain, 2. Kappa/Lambda Ratio.**Pretest Condition**: No fasting required; patients should report anemia, bone pain, or renal symptoms.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on renal function, bone pain, fatigue.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed gammopathy including renal failure, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or renal impairment can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal kappa/lambda ratio (>1.65 or <0.26) indicates monoclonal expansion, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Serum protein electrophoresis, bone marrow biopsy for confirmation.**Test Limitations**: Renal function affects ratio; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Myeloma Studies India 2023. |
